Skip to main content

CRISPR Therapeutics — Deal History & Benchmarks

Total Deals
2
Across 2 therapeutic areas
Total Deal Value
$1.8B
Cumulative transaction value
Most Active Year
2023
2 deals closed
Primary TA
Rare Disease
50% of deal activity
Model Your Deal

Market Analysis

CRISPR Therapeutics has been involved in 2 transactions totaling $1.8B across Rare Disease, Cardiovascular. As both a licensor and licensee, they have demonstrated a collaborative partnership model.

Key transactions include Vertex Pharmaceuticals ($900M, 2023).

Their deal activity is concentrated in Rare Disease (50%) with Gene Therapy (Rare) and Gene Therapy assets representing their most common deal types.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How many deals has CRISPR Therapeutics done?
CRISPR Therapeutics has completed 2 verified transactions tracked in our database, spanning from 2023 to 2023. These deals have a combined value of $1.8B.
What is CRISPR Therapeutics's typical deal structure?
Based on 2 deals, CRISPR Therapeutics's transactions show a median upfront payment of $500M. Their most common deal type is collaboration, reflecting a collaborative partnership model.
What therapeutic areas does CRISPR Therapeutics focus on?
CRISPR Therapeutics is primarily active in Rare Disease (50%), Cardiovascular (50%).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Rare Disease Licensing Benchmarks

View

Gene Therapy Rare Disease Deals

View

Cardiovascular Deal Benchmarks

View

Phase 2 Deal Benchmarks

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included